MIST - Milestone Pharmaceuticals begins etripamil study October, 03 2019 07:05 AM Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals (NASDAQ:MIST) announces that the first patient has been enrolled in the Phase 3 NODE-303 study.More news on: Milestone Pharmaceuticals Inc., Healthcare stocks news, Read more ...